Literature DB >> 21361747

Good manufacturing practice-grade cytotoxic T lymphocytes specific for latent membrane proteins (LMP)-1 and LMP2 for patients with Epstein-Barr virus-associated lymphoma.

Catherine M Bollard1, Stephen Gottschalk, M Helen Huls, Ann M Leen, Adrian P Gee, Cliona M Rooney.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21361747      PMCID： PMC3186062          DOI： 10.3109/14653249.2011.561983

Source DB:  PubMed          Journal:  Cytotherapy        ISSN： 1465-3249            Impact factor:   5.414


× No keyword cloud information.
  11 in total

1.  Large-scale expansion of dendritic cell-primed polyclonal human cytotoxic T-lymphocyte lines using lymphoblastoid cell lines for adoptive immunotherapy.

Authors:  Uluhan Sili; M Helen Huls; Alan R Davis; Stephen Gottschalk; Malcolm K Brenner; Helen E Heslop; Cliona M Rooney
Journal:  J Immunother       Date:  2003 May-Jun       Impact factor: 4.456

2.  Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex).

Authors:  Juan F Vera; Lara J Brenner; Ulrike Gerdemann; Minhtran C Ngo; Uluhan Sili; Hao Liu; John Wilson; Gianpietro Dotti; Helen E Heslop; Ann M Leen; Cliona M Rooney
Journal:  J Immunother       Date:  2010-04       Impact factor: 4.456

3.  Contact-activated monocytes: efficient antigen presenting cells for the stimulation of antigen-specific T cells.

Authors:  Ann Leen; Maheshika Ratnayake; Aaron Foster; Kenneth Heym; Nabil Ahmed; Cliona M Rooney; Stephen Gottschalk
Journal:  J Immunother       Date:  2007-01       Impact factor: 4.456

4.  Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies.

Authors:  Stephen Gottschalk; Oliver L Edwards; Uluhan Sili; M Helen Huls; Tatiana Goltsova; Alan R Davis; Helen E Heslop; Cliona M Rooney
Journal:  Blood       Date:  2002-10-31       Impact factor: 22.113

5.  The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells.

Authors:  S R Riddell; P D Greenberg
Journal:  J Immunol Methods       Date:  1990-04-17       Impact factor: 2.303

6.  Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease.

Authors:  M A Roskrow; N Suzuki; Y j Gan; J W Sixbey; C Y Ng; S Kimbrough; M Hudson; M K Brenner; H E Heslop; C M Rooney
Journal:  Blood       Date:  1998-04-15       Impact factor: 22.113

7.  Release of infectious Epstein-Barr virus by transformed marmoset leukocytes.

Authors:  G Miller; M Lipman
Journal:  Proc Natl Acad Sci U S A       Date:  1973-01       Impact factor: 11.205

8.  The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease.

Authors:  Catherine M Bollard; Karin C M Straathof; M Helen Huls; Alan Leen; Kristine Lacuesta; Alan Davis; Stephen Gottschalk; Malcolm K Brenner; Helen E Heslop; Cliona M Rooney
Journal:  J Immunother       Date:  2004 Jul-Aug       Impact factor: 4.456

9.  Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer.

Authors:  Catherine M Bollard; Stephen Gottschalk; Ann M Leen; Heidi Weiss; Karin C Straathof; George Carrum; Mariam Khalil; Meng-fen Wu; M Helen Huls; Chung-Che Chang; M Victoria Gresik; Adrian P Gee; Malcolm K Brenner; Cliona M Rooney; Helen E Heslop
Journal:  Blood       Date:  2007-07-03       Impact factor: 22.113

10.  Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease.

Authors:  Catherine M Bollard; Laura Aguilar; Karin C Straathof; Benedikt Gahn; M Helen Huls; Alexandra Rousseau; John Sixbey; M Victoria Gresik; George Carrum; Melissa Hudson; Dagmar Dilloo; Adrian Gee; Malcolm K Brenner; Cliona M Rooney; Helen E Heslop
Journal:  J Exp Med       Date:  2004-12-20       Impact factor: 14.307
View more
  12 in total

1.  Expanding cytotoxic T lymphocytes from umbilical cord blood that target cytomegalovirus, Epstein-Barr virus, and adenovirus.

Authors:  Patrick J Hanley; Sharon Lam; Elizabeth J Shpall; Catherine M Bollard
Journal:  J Vis Exp       Date:  2012-05-07       Impact factor: 1.355

2.  Scouting out the neighborhood in AIDS-related lymphoma.

Authors:  Kieron Dunleavy; Catherine M Bollard
Journal:  Blood       Date:  2013-07-18       Impact factor: 22.113

3.  An update from the United States National Heart, Lung, and Blood Institute-funded Production Assistance for Cellular Therapies (PACT) program: a decade of cell therapy.

Authors:  Deborah Wood; Robin Wesselschmidt; Peiman Hematti; Adrian P Gee; Cliona Rooney; Leslie Silberstein; Myriam Armant; Larry Couture; John E Wagner; David H McKenna; Derek Hei; Traci Heath Mondoro; Lisbeth Welniak; Robert Lindblad
Journal:  Clin Transl Sci       Date:  2014-03-21       Impact factor: 4.689

4.  Complementation of antigen-presenting cells to generate T lymphocytes with broad target specificity.

Authors:  Minhtran Charlotte Ngo; Jun Ando; Ann M Leen; Sravya Ennamuri; Natalia Lapteva; Juan F Vera; Amelia Min-Venditti; Martha P Mims; Helen E Heslop; Catherine M Bollard; Stephen Gottschalk; Cliona M Rooney
Journal:  J Immunother       Date:  2014-05       Impact factor: 4.456

Review 5.  EBV+ lymphoproliferative diseases: opportunities for leveraging EBV as a therapeutic target.

Authors:  Keri Toner; Catherine M Bollard
Journal:  Blood       Date:  2022-02-17       Impact factor: 22.113

Review 6.  The generation and application of antigen-specific T cell therapies for cancer and viral-associated disease.

Authors:  Amy B Hont; Allison B Powell; Danielle K Sohai; Izabella K Valdez; Maja Stanojevic; Ashley E Geiger; Kajal Chaudhary; Ehsan Dowlati; Catherine M Bollard; Conrad Russell Y Cruz
Journal:  Mol Ther       Date:  2022-02-09       Impact factor: 12.910

7.  Generation of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplant.

Authors:  G Weber; U Gerdemann; I Caruana; B Savoldo; N F Hensel; K R Rabin; E J Shpall; J J Melenhorst; A M Leen; A J Barrett; C M Bollard
Journal:  Leukemia       Date:  2013-03-01       Impact factor: 11.528

8.  Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins.

Authors:  Catherine M Bollard; Stephen Gottschalk; Vicky Torrano; Oumar Diouf; Stephanie Ku; Yasmin Hazrat; George Carrum; Carlos Ramos; Luis Fayad; Elizabeth J Shpall; Barbara Pro; Hao Liu; Meng-Fen Wu; Daniel Lee; Andrea M Sheehan; Youli Zu; Adrian P Gee; Malcolm K Brenner; Helen E Heslop; Cliona M Rooney
Journal:  J Clin Oncol       Date:  2013-12-16       Impact factor: 44.544

9.  EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation.

Authors:  Lauren P McLaughlin; Rayne Rouce; Stephen Gottschalk; Vicky Torrano; George Carrum; Meng-Fen Wu; Fahmida Hoq; Bambi Grilley; Andrea M Marcogliese; Patrick J Hanley; Adrian P Gee; Malcolm K Brenner; Cliona M Rooney; Helen E Heslop; Catherine M Bollard
Journal:  Blood       Date:  2018-09-27       Impact factor: 25.476

10.  Optimizing the production of suspension cells using the G-Rex "M" series.

Authors:  Pradip Bajgain; Roopa Mucharla; John Wilson; Dan Welch; Usanarat Anurathapan; Bitao Liang; Xiaohua Lu; Kyle Ripple; John M Centanni; Christine Hall; David Hsu; Larry A Couture; Shubhranshu Gupta; Adrian P Gee; Helen E Heslop; Ann M Leen; Cliona M Rooney; Juan F Vera
Journal:  Mol Ther Methods Clin Dev       Date:  2014-05-14       Impact factor: 6.698
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.